Cadila Healthcare gains as unit acquires experimental drug from Cyprium
Cadila Healthcare rose 1.12% to Rs 438.75 after the pharmaceutical company said that its US subsidiary has acquired experimental drug from Cyprium for treating Menkes disease. Cyprium Therapeutics, a partner of Fortress Biotech, and Sentynl Therapeutics, a U.S.- based specialty pharmaceutical company owned by the Zydus Group, has announced its execution of an asset purchase agreement to commit development funding for and acquire Cyprium's proprietary rights to CUTX-101, its Copper Histidinate product candidate for the treatment of Menkes disease. Menkes disease is a rare X-linked recessive p...